在布基纳法索，蒿甲醚-本芴醇和双氢青蒿素-哌喹对恶性疟原虫Pfcrt和Pfmdr1变体的体内选择
In vivo selection of Plasmodium falciparum Pfcrt and Pfmdr1 variants by artemether-lumefantrine and dihydroartemisinin-piperaquine in Burkina Faso.
作者信息
Baraka Vito, Tinto Halidou, Valea Innocent, Fitzhenry Robert, Delgado-Ratto Christopher, Mbonye Martin K, Van Overmeir Chantal, Rosanas-Urgell Anna, Van Geertruyden Jean-Pierre, D'Alessandro Umberto, Erhart Annette
机构信息
National Institute for Medical Research, Tanga Medical Research Centre, Tanga, United Republic of Tanzania International Health Unit, Department of Epidemiology, University of Antwerp, Antwerp, Belgium
Centre Muraz, Bobo Dioulasso, Burkina Faso.
出版信息
Antimicrob Agents Chemother. 2015 Jan;59(1):734-7. doi: 10.1128/AAC.03647-14. Epub 2014 Nov 17.
Abstract
Plasmodium falciparum Pfcrt-76 and Pfmdr1-86 gene polymorphisms were determined during a clinical trial in Burkina Faso comparing the efficacies of dihydroartemisinin-piperaquine (DHA-PPQ) and artemether-lumefantrine (AL). Significant selection of Pfcrt-K76 was observed after exposure to AL and DHA-PPQ, as well as selection of Pfmdr1-N86 after AL but not DHA-PPQ treatment, suggesting reverse selection on the Pfcrt gene by PPQ. These results support the rational use of DHA-PPQ in settings where chloroquine (CQ) resistance is high.
摘要
在布基纳法索进行的一项临床试验中，比较了双氢青蒿素-哌喹（DHA-PPQ）和蒿甲醚-本芴醇（AL）的疗效，同时测定了恶性疟原虫Pfcrt-76和Pfmdr1-86基因多态性。在接受AL和DHA-PPQ治疗后，观察到Pfcrt-K76有显著选择，在接受AL治疗后但DHA-PPQ治疗后未观察到Pfmdr1-N86选择，这表明PPQ对Pfcrt基因有反向选择作用。这些结果支持在氯喹（CQ）耐药性高的地区合理使用DHA-PPQ。
相似文献
1
In vivo selection of Plasmodium falciparum Pfcrt and Pfmdr1 variants by artemether-lumefantrine and dihydroartemisinin-piperaquine in Burkina Faso.在布基纳法索，蒿甲醚-本芴醇和双氢青蒿素-哌喹对恶性疟原虫Pfcrt和Pfmdr1变体的体内选择
Antimicrob Agents Chemother. 2015 Jan;59(1):734-7. doi: 10.1128/AAC.03647-14. Epub 2014 Nov 17.
2
Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso.在布基纳法索，青蒿琥酯-咯萘啶和阿莫地喹-磺胺多辛-乙胺嘧啶选择已知的疟原虫耐药相关多态性，但二氢青蒿素-哌喹没有。
Antimicrob Agents Chemother. 2010 May;54(5):1949-54. doi: 10.1128/AAC.01413-09. Epub 2010 Mar 15.
3
Selection of Plasmodium falciparum pfcrt and pfmdr1 polymorphisms after treatment with artesunate-amodiaquine fixed dose combination or artemether-lumefantrine in Liberia.在利比里亚，用青蒿琥酯-阿莫地喹固定剂量复方或蒿甲醚-本芴醇治疗后恶性疟原虫pfcrt和pfmdr1基因多态性的选择
Malar J. 2016 Sep 5;15(1):452. doi: 10.1186/s12936-016-1503-3.
4
In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa.在非洲用蒿甲醚-本芴醇治疗后，体内选择携带对氯喹敏感的恶性疟原虫pfcrt K76等位基因的疟原虫。
J Infect Dis. 2009 Mar 1;199(5):750-7. doi: 10.1086/596738.
5
Artesunate-Amodiaquine and Artemether-Lumefantrine Therapies and Selection of Pfcrt and Pfmdr1 Alleles in Nanoro, Burkina Faso.在布基纳法索纳诺罗地区青蒿琥酯-阿莫地喹和蒿甲醚-本芴醇疗法以及Pfcrt和Pfmdr1等位基因的选择
PLoS One. 2016 Mar 31;11(3):e0151565. doi: 10.1371/journal.pone.0151565. eCollection 2016.
6
Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine.疟原虫氯喹耐药转运体和多药耐药基因 1 多态性：影响青蒿琥酯-咯萘啶和青蒿琥酯-阿莫地喹治疗恶性疟原虫疟疾后治疗结局的寄生虫危险因素。
Am J Trop Med Hyg. 2014 Oct;91(4):833-843. doi: 10.4269/ajtmh.14-0031. Epub 2014 Jul 21.
7
Sustained Susceptibility of Plasmodium falciparum to Artemisinin Derivatives but Increasing Tolerance to Artemisinin Combination Therapy Partner Quinolines in The Gambia.冈比亚恶性疟原虫对青蒿素衍生物持续敏感，但对青蒿素联合疗法中的喹啉类药物耐受性增加。
Antimicrob Agents Chemother. 2017 Nov 22;61(12). doi: 10.1128/AAC.00759-17. Print 2017 Dec.
8
Selection of K76 and N86 Coding Alleles after Uncomplicated Malaria Treatment by Artemether-Lumefantrine in Mali.在马里使用青蒿琥酯-咯萘啶治疗无并发症疟疾后 K76 和 N86 编码等位基因的选择。
Int J Mol Sci. 2021 Jun 3;22(11):6057. doi: 10.3390/ijms22116057.
9
Changing Antimalarial Drug Sensitivities in Uganda.乌干达抗疟药物敏感性变化。
Antimicrob Agents Chemother. 2017 Nov 22;61(12). doi: 10.1128/AAC.01516-17. Print 2017 Dec.
10
Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria in Papua New Guinea.青蒿琥酯-咯萘啶和双氢青蒿素-哌喹治疗巴布亚新几内亚无并发症疟疾的疗效。
Malar J. 2018 Oct 5;17(1):350. doi: 10.1186/s12936-018-2494-z.
引用本文的文献
1
Plasmodium falciparum multidrug resistance 1 gene polymorphisms associated with outcomes after anti-malarial treatment.恶性疟原虫多药耐药1基因多态性与抗疟治疗后的结局相关。
Malar J. 2025 Jun 12;24(1):186. doi: 10.1186/s12936-025-05248-2.
2
Plasmodium falciparum isolates: ex vivo drug response.恶性疟原虫分离株：体外药物反应
J Antimicrob Chemother. 2025 Jul 1;80(7):1813-1822. doi: 10.1093/jac/dkaf129.
3
Trend of N86Y and Y184F Mutations in Pfmdr1 Gene in Children Under Seasonal Malaria Chemoprevention Coverage in Nanoro, Burkina Faso.布基纳法索纳诺罗地区接受季节性疟疾化学预防的儿童中Pfmdr1基因N86Y和Y184F突变的趋势
Acta Parasitol. 2024 Dec;69(4):1967-1976. doi: 10.1007/s11686-024-00923-x. Epub 2024 Oct 2.
4
Characterization of Plasmodium Falciparum Resistance Genes to Common Antimalarial Drugs in Semi-urban Areas of Burkina Faso.布基纳法索半城市地区恶性疟原虫对常见抗疟药物耐药基因的特征。
Acta Parasitol. 2024 Mar;69(1):910-921. doi: 10.1007/s11686-024-00826-x. Epub 2024 Mar 13.
5
Breaking the cycle of malaria treatment failure.打破疟疾治疗失败的循环。
Front Epidemiol. 2022 Dec 14;2:1041896. doi: 10.3389/fepid.2022.1041896. eCollection 2022.
6
Assessing emergence risk of double-resistant and triple-resistant genotypes of Plasmodium falciparum.评估疟原虫双耐药和三耐药基因型的出现风险。
Nat Commun. 2024 Feb 15;15(1):1390. doi: 10.1038/s41467-024-45547-x.
7
Temporal evolution of the resistance genotypes of Plasmodium falciparum in isolates from Equatorial Guinea during 20 years (1999 to 2019).赤道几内亚疟原虫分离株 20 年（1999 年至 2019 年）耐药基因型的时间演变。
Malar J. 2021 Dec 14;20(1):463. doi: 10.1186/s12936-021-04000-w.
8
First Detection in West Africa of a Mutation That May Contribute to Artemisinin Resistance .在西非首次检测到可能导致青蒿素耐药性的一种突变。
Front Genet. 2021 Oct 8;12:701750. doi: 10.3389/fgene.2021.701750. eCollection 2021.
9
Decreased prevalence of the Plasmodium falciparum Pfcrt K76T and Pfmdr1 and N86Y mutations post-chloroquine treatment withdrawal in Katete District, Eastern Zambia.赞比亚东部卡特特地区停用氯喹后恶性疟原虫 PfCRT K76T 和 PfMDR1 N86Y 突变的流行率降低。
Malar J. 2021 Jul 28;20(1):329. doi: 10.1186/s12936-021-03859-z.
10
Prevalence of pfk13 and pfmdr1 polymorphisms in Bounkiling, Southern Senegal.塞内加尔南部布恩基林地区 pfk13 和 pfmdr1 多态性的流行情况。
PLoS One. 2021 Mar 26;16(3):e0249357. doi: 10.1371/journal.pone.0249357. eCollection 2021.
本文引用的文献
1
Selection of drug resistance-mediating Plasmodium falciparum genetic polymorphisms by seasonal malaria chemoprevention in Burkina Faso.布基纳法索季节性疟疾化学预防对介导耐药性的恶性疟原虫基因多态性的选择
Antimicrob Agents Chemother. 2014 Jul;58(7):3660-5. doi: 10.1128/AAC.02406-14. Epub 2014 Apr 14.
2
Comparative impacts over 5 years of artemisinin-based combination therapies on Plasmodium falciparum polymorphisms that modulate drug sensitivity in Ugandan children.基于青蒿素的联合疗法对乌干达儿童中调节药物敏感性的恶性疟原虫多态性的5年比较影响。
J Infect Dis. 2014 Aug 1;210(3):344-53. doi: 10.1093/infdis/jiu141. Epub 2014 Mar 8.
3
Piperaquine resistance is associated with a copy number variation on chromosome 5 in drug-pressured Plasmodium falciparum parasites.哌喹耐药性与药物压力下恶性疟原虫染色体 5 上的拷贝数变异有关。
Antimicrob Agents Chemother. 2011 Aug;55(8):3908-16. doi: 10.1128/AAC.01793-10. Epub 2011 May 16.
4
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.在恶性疟原虫中，哌喹体外反应与 pfcrt、pfmdr1、pfmrp 和 pfnhe 基因多态性之间无关联。
Antimicrob Agents Chemother. 2010 Sep;54(9):3537-44. doi: 10.1128/AAC.00183-10. Epub 2010 Jun 14.
5
Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso.在布基纳法索，青蒿琥酯-咯萘啶和阿莫地喹-磺胺多辛-乙胺嘧啶选择已知的疟原虫耐药相关多态性，但二氢青蒿素-哌喹没有。
Antimicrob Agents Chemother. 2010 May;54(5):1949-54. doi: 10.1128/AAC.01413-09. Epub 2010 Mar 15.
6
In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.在乌干达，体外疟原虫对不同抗疟药物的敏感性。
Antimicrob Agents Chemother. 2010 Mar;54(3):1200-6. doi: 10.1128/AAC.01412-09. Epub 2010 Jan 11.
7
Selection of pfmdr1 and pfcrt alleles in amodiaquine treatment failure in north-western Burkina Faso.在布基纳法索西北部的抗疟喹啉治疗失败中 pfmdr1 和 pfcrt 等位基因的选择。
Acta Trop. 2010 Apr;114(1):63-6. doi: 10.1016/j.actatropica.2009.12.008. Epub 2010 Jan 7.
8
Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial.双氢青蒿素-哌喹与青蒿琥酯-咯萘啶治疗非洲儿童无并发症疟疾：一项随机、非劣效性试验。
PLoS One. 2009 Nov 17;4(11):e7871. doi: 10.1371/journal.pone.0007871.
9
In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.在肯尼亚恶性疟原虫分离株中哌喹、青蒿琥酯和二氢青蒿素的体外活性以及 pfcrt 和 pfmdr1 的多态性。
Antimicrob Agents Chemother. 2009 Dec;53(12):5069-73. doi: 10.1128/AAC.00638-09. Epub 2009 Sep 21.
10
Artemisinin resistance in Plasmodium falciparum malaria.恶性疟原虫疟疾中的青蒿素耐药性。
N Engl J Med. 2009 Jul 30;361(5):455-67. doi: 10.1056/NEJMoa0808859.
Zotero 插件